California State Teachers Retirement System Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

California State Teachers Retirement System reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 167,889 shares of the biopharmaceutical company's stock after selling 5,256 shares during the quarter. California State Teachers Retirement System owned 0.15% of Regeneron Pharmaceuticals worth $119,592,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Pamalican Asset Management Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $4,915,000. Intact Investment Management Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $356,000. Rhenman & Partners Asset Management AB lifted its stake in Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after purchasing an additional 4,457 shares during the last quarter. Principal Financial Group Inc. boosted its position in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after buying an additional 2,828 shares during the period. Finally, Fagan Associates Inc. grew its stake in shares of Regeneron Pharmaceuticals by 42.2% during the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after buying an additional 3,832 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $15.61 during midday trading on Friday, hitting $605.61. 1,606,415 shares of the stock traded hands, compared to its average volume of 744,231. The firm has a market capitalization of $66.21 billion, a P/E ratio of 15.82, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a 50-day moving average of $628.85 and a two-hundred day moving average of $714.29.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the company posted $9.55 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. StockNews.com cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating for the company in a report on Wednesday. The Goldman Sachs Group cut their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $892.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.